{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T08:21:01Z","timestamp":1776586861177,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T00:00:00Z","timestamp":1439769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T00:00:00Z","timestamp":1439769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients receive dual antiplatelet therapy (DAPT) for 6\u201312 months after drug-eluting stents (DES) implantation. The efficacy and safety of prolonged DAPT has been questioned. Therefore, we performed a meta-analysis on randomised trials comparing different DAPT durations. Literature was searched on trials comparing different DAPT durations. For inclusion, reports must report frequency of cardiovascular and bleeding events. Ten trials were included. Compared to 12 months, DAPT beyond 12 months was associated with fewer myocardial infarctions (OR 0.58 95%CI: 0.40\u20130.84) and stent thrombosis (OR 0.35 95%CI: 0.20\u20130.62), but more major bleeds (OR 1.60 95%CI: 1.22\u20132.11) and all-cause (OR 1.30 95%CI: 1.02\u20131.66) mortality. There was no significant alteration in risk of stroke (OR 0.93 95%CI: 0.66\u20131.31) or cardiac (OR 1.12 95%CI: 0.73\u20131.71) mortality. Compared to less than 12 months DAPT, 12 months DAPT did not reduce risk of myocardial infarction, stent thrombosis, strokes, cardiac or all-cause mortality, but increased the risk of major bleeds (OR 1.60 95%CI: 1.22\u20132.11). DAPT beyond 12 months reduce risk of myocardial infarction and stent thrombosis, but there is substantial increase in major bleeding risk and all-cause mortality which need to be addressed. DAPT beyond 12 months does not appear to alter the risk of stroke.<\/jats:p>","DOI":"10.1038\/srep13204","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T11:12:58Z","timestamp":1439809978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of large randomised controlled trials"],"prefix":"10.1038","volume":"5","author":[{"given":"Man-Fung","family":"Tsoi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Lung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommy Tsang","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian Chi-Kei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus Rustam","family":"Kumana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Fat","family":"Tse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard Man-Yung","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,8,17]]},"reference":[{"key":"BFsrep13204_CR1","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht310.P4876","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot, G. et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 34, 2949\u20133003 (2013).","journal-title":"Eur. Heart J."},{"key":"BFsrep13204_CR2","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"CW Hamm","year":"2011","unstructured":"Hamm, C. W. et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32, 2999\u20133054 (2011).","journal-title":"Eur. Heart J."},{"key":"BFsrep13204_CR3","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","volume":"125","author":"HC Gwon","year":"2012","unstructured":"Gwon, H. C. et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: The efficacy of xience\/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 125, 505\u2013513 (2012).","journal-title":"Circulation"},{"key":"BFsrep13204_CR4","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","volume":"60","author":"BK Kim","year":"2012","unstructured":"Kim, B. K. et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J. Am. Coll. Cardiol. 60, 1340\u20131348 (2012).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep13204_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","volume":"125","author":"M Valgimigli","year":"2012","unstructured":"Valgimigli, M. et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: A randomized multicenter trial. Circulation 125, 2015\u20132026 (2012).","journal-title":"Circulation"},{"key":"BFsrep13204_CR6","first-page":"2510","volume":"310","author":"F Feres","year":"2013","unstructured":"Feres, F. et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: The OPTIMIZE randomized trial. JAMA 310, 2510\u20132522 (2013).","journal-title":"JAMA"},{"key":"BFsrep13204_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","volume":"384","author":"JP Collet","year":"2014","unstructured":"Collet, J. P. et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 384, 1577\u20131585 (2014).","journal-title":"Lancet"},{"key":"BFsrep13204_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","volume":"64","author":"A Colombo","year":"2014","unstructured":"Colombo, A. et al. Second-Generation Drug-Eluting Stent Implantation Followed by 6- Versus 12-Month Dual Antiplatelet Therapy: The SECURITY Randomized Clinical Trial. J. Am. Coll. Cardiol. 64, 2086\u20132097 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep13204_CR9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","volume":"65","author":"M Gilard","year":"2015","unstructured":"Gilard, M. et al. Six-month versus 24-month dual antiplatelet therapy after implantation of drug eluting stents in patients non-resistant to aspirin: ITALIC, a randomized multicenter trial. J. Am. Coll. Cardiol. 65, 777\u2013786 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"BFsrep13204_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","volume":"129","author":"CW Lee","year":"2014","unstructured":"Lee C. W. et al. Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Randomized, Controlled Trial. Circulation 129, 304\u2013312 (2014).","journal-title":"Circulation"},{"key":"BFsrep13204_CR11","doi-asserted-by":"crossref","unstructured":"Mauri, L. et al. Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N. Engl. J. Med. 10.1056\/NEJMoa1409312 (2014).","DOI":"10.1056\/NEJMoa1409312"},{"key":"BFsrep13204_CR12","unstructured":"Schulz-Schupke, S. et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. European heart journal 10.1093\/eurheartj\/ehu523 (2015)."},{"key":"BFsrep13204_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.amjcard.2014.04.035","volume":"114","author":"G El-Hayek","year":"2014","unstructured":"El-Hayek, G. et al. Meta-analysis of randomized clinical trials comparing short-term versus long-term dual antiplatelet therapy following drug-eluting stents. Am. J. Cardiol. 114, 236\u2013242 (2014).","journal-title":"Am. J. Cardiol."},{"key":"BFsrep13204_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip, G. Y., Nieuwlaat, R., Pisters, R., Lane, D. A. & Crijns, H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 137, 263\u2013272 (2010).","journal-title":"Chest."},{"key":"BFsrep13204_CR15","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.282.20.1899","volume":"282","author":"CR Kumana","year":"1999","unstructured":"Kumana, C. R., Cheung B. M. Y. & Lauder I. J. Gauging the impact of statins using number needed to treat. JAMA 282, 1899\u20131901 (1999).","journal-title":"JAMA"},{"key":"BFsrep13204_CR16","doi-asserted-by":"crossref","unstructured":"Pandit A., Giri, S., Hakim, F. A. & Fortuin, S. F. D. (&lt;\/=6 months) versus longer (&gt;\/=12 months) duration dual antiplatelet therapy after drug eluting stents: A meta-analysis of randomized clinical trials. Catheter Cardio. Inte. 10.1002\/ccd.25520 (2014).","DOI":"10.1002\/ccd.25520"},{"key":"BFsrep13204_CR17","unstructured":"Elmariah, S. et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet 10.1016\/S0140-6736(14)62052-3 (2014)."},{"key":"BFsrep13204_CR18","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters, R. et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 138, 1093\u20131100 (2010).","journal-title":"Chest."},{"key":"BFsrep13204_CR19","doi-asserted-by":"crossref","unstructured":"Palmerini, T. et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 10.1016\/s0140-6736(15)60263-x (2015).","DOI":"10.1016\/S0140-6736(15)60263-X"},{"key":"BFsrep13204_CR20","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","volume":"65","author":"G Giustino","year":"2015","unstructured":"Giustino, G. et al. Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 65, 1298\u20131310 (2015).","journal-title":"J Am Coll Cardiol"},{"key":"BFsrep13204_CR21","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jacc.2014.12.046","volume":"65","author":"T Palmerini","year":"2015","unstructured":"Palmerini, T. et al. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis. J Am Coll Cardiol 65, 1092\u20131102 (2015).","journal-title":"J Am Coll Cardiol"},{"key":"BFsrep13204_CR22","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MCA.0000000000000078","volume":"24","author":"C1 Machado","year":"2014","unstructured":"Machado, C1. et al. Second-generation versus first-generation drug-eluting stents for the treatment of patients with acute coronary syndromes and obstructive coronary artery disease. Coron. Artery Dis. 24, 208\u2013214 (2014).","journal-title":"Coron. Artery Dis."},{"key":"BFsrep13204_CR23","doi-asserted-by":"crossref","unstructured":"Shimamura, K. et al. Outcomes of everolimus-eluting stent incomplete stent apposition: a serial optical coherence tomography analysis. Eur. Heart. J. Cardiovasc. Imaging 10.1093\/ehjci\/jeu174 (2014).","DOI":"10.1016\/S0735-1097(14)61797-6"},{"key":"BFsrep13204_CR24","doi-asserted-by":"crossref","unstructured":"Kaiser, C. et al. Long-Term Efficacy and Safety of Biodegradable-Polymer Biolimus-Eluting Stents: Main Results of the Basel Stent Kosten-Effektivit\u00e4ts Trial- PROspective Validation Examination II (BASKET-PROVE II), A Randomized, Controlled Noninferiority 2-Year Outcome Trial. Circulation 10.1161\/CIRCULATIONAHA.114.013520 (2014).","DOI":"10.1161\/CIRCULATIONAHA.114.013520"},{"key":"BFsrep13204_CR25","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","volume":"123","author":"R Mehran","year":"2011","unstructured":"Mehran, R. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123, 2736\u20132747 (2011).","journal-title":"Circulation"},{"key":"BFsrep13204_CR26","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1161\/CIR.0b013e31826e1058","volume":"126","author":"K Thygesen","year":"2012","unstructured":"Thygesen, K., Alpert, J. S. & Jaffe, A. S. et al. Third universal definition of myocardial infarction. Circulation 126, 2020\u20132035 (2012).","journal-title":"Circulation"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep13204","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep13204.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T22:30:50Z","timestamp":1672957850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep13204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,10,16]]}},"alternative-id":["BFsrep13204"],"URL":"https:\/\/doi.org\/10.1038\/srep13204","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,17]]},"assertion":[{"value":"25 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HF Tse reported grants and personal fees from AstraZeneca, grants and personal fees from Sanofi, grants and personal fees from MSD, grants and personal fees from Pfizer, grants and personal fees from BMS, grants and personal fees from Boehringer-Ingelheim, outside the submitted work; other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13204"}}